Comment from Long Grove Pharmaceuticals, LLC

Summary: Long Grove Pharmaceuticals, LLC, opposes the inclusion of norepinephrine bitartrate on the 503B bulks list, arguing that the drug is "essentially a copy" of their already FDA-approved product. They contend there is no clinical need for compounding from bulk drug substances and express concerns regarding the quality and safety of products from outsourcing facilities.